A fog-lit field guide to the four-peptide KLOW research blend — KPV, GHK-Cu, BPC-157 and TB-500 traced arm by arm through the tissue-repair cascade, the mechanism read first and the missing blend data named for what it is.
Prescribed KLOW

BLEND COMPARISON · MECHANISM

KLOW vs GLOW: How the Two Peptide Blends Compare

KLOW and GLOW share three arms. KLOW adds a fourth: KPV, the anti-inflammatory tripeptide. What that arm does — and why the distinction matters — is the substance of this page.

Inside the KLOW stackKLOW research

The short version

KLOW and GLOW are related research blends. GLOW is a three-peptide blend of GHK-Cu, BPC-157 and TB-500. KLOW is those same three components plus a fourth: KPV (Lys-Pro-Val), the anti-inflammatory tripeptide. In terms of mechanism, the KPV addition is the defining distinction. In terms of composition, KLOW carries more total peptide content (80 mg total vs GLOW's typical 40–50 mg total) because GHK-Cu's dominant share is proportionally larger in the KLOW vial. Neither blend has been tested in a controlled study.

Composition side by side

KLOW (four peptides, 80 mg total):

  • GHK-Cu: 50 mg (~62.5%)
  • BPC-157: 10 mg (12.5%)
  • TB-500: 10 mg (12.5%)
  • KPV: 10 mg (12.5%)

GLOW (three peptides, typical 40–50 mg total):

  • GHK-Cu: the largest share (the same mass-dominant role)
  • BPC-157: a smaller share
  • TB-500: a smaller share
  • KPV: absent

The GHK-Cu arm is mass-dominant in both blends. The three shared components — GHK-Cu (matrix/copper), BPC-157 (angiogenic), TB-500 (cytoskeletal) — perform the same mechanistic roles in both. The KLOW-specific contribution is the KPV arm: the anti-inflammatory NF-κB-blocking, MAPK-suppressing tripeptide that is taken up via PepT1 into inflamed epithelial and immune cells [3].

KLOW blend — what KPV adds to the GLOW three-arm formula

KPV's mechanism is upstream of repair. Before collagen crosslinking (GHK-Cu), before new vessels (BPC-157) and before cell migration (TB-500) can be fully effective, the inflammatory signaling driving tissue destruction needs to be dampened. KPV addresses that step: it blocks NF-κB nuclear import and reduces TNF-α, IL-6 and IL-1β output in inflamed tissue at nanomolar concentrations [3].

The combination rationale for KLOW vs GLOW is therefore temporal as well as spatial: the KPV arm theoretically prepares an inflamed tissue environment for the repair signaling the three GLOW components then deliver. This is plausible mechanistically. Whether it produces measurably better outcomes than GLOW alone — in any tissue, at any dose, in any species — has not been tested.

The PepT1 uptake route also has a practical implication: KPV's absorption into tissue is favored where PepT1 expression is upregulated, i.e. in inflamed gut epithelium and activated macrophages. The GLOW blend's three arms do not use this transporter. The KPV arm in KLOW is therefore tissue-selective in a way that the other three arms are not.

How they differ on the regulatory and safety profile

KLOW and GLOW share the same key safety considerations for the three overlapping arms: TB-500 / thymosin beta-4 is WADA S2 prohibited at all times (both blends carry this arm [7]); BPC-157 is FDA 503A category 2 (both blends); three components are pro-angiogenic, raising the same mechanistic cancer caution; GHK-Cu delivers a copper load in both.

The KPV arm adds a further consideration specific to KLOW: immunomodulation. Because KPV suppresses inflammatory signaling via NF-κB and MAPK [3], it introduces the theoretical consideration that matters more in KLOW than in GLOW — dampening immune activation during an active infection or creating unpredictable variables in autoimmune disease.

Neither blend is FDA-approved. Neither has been tested in a controlled human study. The KLOW and GLOW comparison is a mechanistic one, not a clinical one.